FRTX Stock Overview
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States.
Fresh Tracks Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.87|
|52 Week High||US$34.16|
|52 Week Low||US$1.67|
|1 Month Change||-24.90%|
|3 Month Change||-53.02%|
|1 Year Change||-93.89%|
|3 Year Change||-99.00%|
|5 Year Change||n/a|
|Change since IPO||-99.11%|
Recent News & Updates
Brickell Biotech changes name to Fresh Tracks Therapeutics
Clinical-stage biotech Brickell Biotech, Inc. (NASDAQ:BBI) announced a major rebranding exercise on Wednesday, renaming its corporate identity to Fresh Tracks Therapeutics, Inc. Accordingly, the company said that BBI’s name, logo, website, and branding would change to reflect the company’s new strategic shift towards autoimmune, inflammatory, and other diseases. In line with the rebranding, the company’s common stock will begin trading under the new Nasdaq ticker symbol “FRTX” from Thursday. Meanwhile, in connection with the rebranding, the company has formed a Scientific Advisory Board (SAB), which comprises experts in immunology and inflammation. SAB will guide the management and board as the company targets autoimmune and inflammatory diseases with early-stage candidate FRTX-02, pre-clinical asset FRTX-10, and the next-generation kinase inhibitor platform. FRTX-02, formerly known as BBI-02, is undergoing a Phase 1 trial for atopic dermatitis with topline data expected in early 2023.
|FRTX||US Biotechs||US Market|
Return vs Industry: FRTX underperformed the US Biotechs industry which returned -25.6% over the past year.
Return vs Market: FRTX underperformed the US Market which returned -23.2% over the past year.
|FRTX Average Weekly Movement||15.5%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.8%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: FRTX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: FRTX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022.
Fresh Tracks Therapeutics Fundamentals Summary
|FRTX fundamental statistics|
Is FRTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|FRTX income statement (TTM)|
|Cost of Revenue||US$21.22m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-9.96|
|Net Profit Margin||-643.48%|
How did FRTX perform over the long term?See historical performance and comparison
Is FRTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for FRTX?
Other financial metrics that can be useful for relative valuation.
|What is FRTX's n/a Ratio?|
Price to Sales Ratio vs Peers
How does FRTX's PS Ratio compare to its peers?
|FRTX PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
USRM U.S. Stem Cell
FRTX Fresh Tracks Therapeutics
Price-To-Sales vs Peers: FRTX is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (11.6x).
Price to Earnings Ratio vs Industry
How does FRTX's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: FRTX is good value based on its Price-To-Sales Ratio (1.2x) compared to the US Biotechs industry average (13.2x)
Price to Sales Ratio vs Fair Ratio
What is FRTX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||1.2x|
|Fair PS Ratio||0.09x|
Price-To-Sales vs Fair Ratio: FRTX is expensive based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).
Share Price vs Fair Value
What is the Fair Price of FRTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate FRTX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate FRTX's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Fresh Tracks Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FRTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FRTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FRTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FRTX's revenue (29% per year) is forecast to grow faster than the US market (7.7% per year).
High Growth Revenue: FRTX's revenue (29% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FRTX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Fresh Tracks Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FRTX is currently unprofitable.
Growing Profit Margin: FRTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FRTX is unprofitable, and losses have increased over the past 5 years at a rate of 28.9% per year.
Accelerating Growth: Unable to compare FRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FRTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: FRTX has a negative Return on Equity (-191.07%), as it is currently unprofitable.
Discover strong past performing companies
How is Fresh Tracks Therapeutics's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: FRTX's short term assets ($18.3M) exceed its short term liabilities ($2.9M).
Long Term Liabilities: FRTX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: FRTX is debt free.
Reducing Debt: FRTX had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FRTX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: FRTX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 26.6% each year
Discover healthy companies
What is Fresh Tracks Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Fresh Tracks Therapeutics Dividend Yield vs Market|
|Company (Fresh Tracks Therapeutics)||n/a|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Biotechs)||2.8%|
|Analyst forecast in 3 Years (Fresh Tracks Therapeutics)||n/a|
Notable Dividend: Unable to evaluate FRTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FRTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FRTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FRTX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as FRTX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rob Brown (60 yo)
Attorney. Robert Busard Brown, also known as Rob, serves as Chief Executive Officer and Director at Fresh Tracks Therapeutics, Inc. (formerly known as Brickell Biotech, Inc.) since joining on January 1, 20...
CEO Compensation Analysis
|Rob Brown's Compensation vs Fresh Tracks Therapeutics Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$1m||US$468k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$1m||US$450k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$1m||US$450k|
Compensation vs Market: Rob's total compensation ($USD1.33M) is above average for companies of similar size in the US market ($USD781.86K).
Compensation vs Earnings: Rob's compensation has increased whilst the company is unprofitable.
Experienced Management: FRTX's management team is considered experienced (2.8 years average tenure).
Experienced Board: FRTX's board of directors are seasoned and experienced ( 12.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 57.1%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Fresh Tracks Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Fresh Tracks Therapeutics, Inc.
- Ticker: FRTX
- Exchange: NasdaqCM
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$5.610m
- Shares outstanding: 3.00m
- Website: https://www.frtx.com
Number of Employees
- Fresh Tracks Therapeutics, Inc.
- 5777 Central Avenue
- Suite 102
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|FRTX||NasdaqCM (Nasdaq Capital Market)||Yes||New Common Stock||US||USD||Sep 2019|
|VCC||DB (Deutsche Boerse AG)||Yes||New Common Stock||DE||EUR||Sep 2019|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/03 00:00|
|End of Day Share Price||2022/10/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.